ArticleEuropean journal of haematology2026

Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.

Catherine Thieblemont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.